- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02176772
Iron Absorption and Utilization During Tuberculosis and After Treatment
The Effects of Tuberculosis on Dietary Iron Absorption and Systemic Iron Utilization: a Double Stable Isotope Study in Bagamoyo, Tanzania
Background: The disease burden of tuberculosis (TB), second only to HIV/AIDS among infectious diseases, is a major public health problem in developing countries. Accumulating evidence suggests that iron status is a primary determinant of TB progression. Anaemia is prevalent in patients with TB, particularly in sub-Saharan Africa, and associated with increased mortality. Anaemia in TB may be due to inflammation, dietary iron deficiency, or both, and distinguishing among these aetiologies is difficult. Iron supplementation is commonly used to treat anaemia in TB patients, but may be unnecessary if inflammation is the cause. Body iron sequestered by TB inflammation can be mobilized during treatment and used to correct the anaemia. Moreover, supplemental iron may be retained within macrophages, potentially increasing susceptibility to TB and leading to a poorer clinical outcome. Thus, better understanding of iron metabolism during TB and the aetiology of TB-related anaemia would clarify the potential role of iron in pathogenesis and optimal management of the disease.
The investigators hypothesize that: a) TB will increase circulating hepcidin and thereby impair dietary iron absorption and systemic utilization of iron, resulting in iron sequestration and anaemia; b) TB treatment and resolution of inflammation over 6 months will decrease circulating hepcidin, correcting these impairments and improving iron status and hemoglobin; c) the majority of iron utilized to replenish hemoglobin during recovery from TB will come from mobilization of sequestered iron stores rather than from iron absorption.
Objectives: Use iron stable isotopes to characterize iron balance over six months of TB treatment, and specifically to: a) quantify oral and intravenous iron incorporation (oral absorption and systemic iron utilization) at three time points during TB treatment (acute disease, after the intensive treatment phase and at completion of the continuation treatment phase); and b) determine the effect of treatment on iron mobilization from stores to replenish hemoglobin.
Methods/Subjects: Using a triple stable-isotope technique, iron absorption from labelled test meals (57Fe) and systemic iron utilization after labelled intravenous doses (54Fe, 58Fe) will be determined in 18 Tanzanian subjects with newly diagnosed pulmonary TB. The subjects will be studied at three time points (i) the day after TB diagnosis while infected, (ii) after 8 weeks of intensive phase treatment, and (iii) after another 16 weeks of continuation phase treatment. Iron status, hemoglobin, hepcidin and inflammation indexes will be measured at each time point. Isotope enrichment during the two treatment phases will be measured to estimate the relative rates of iron absorption and mobilization from stores during the intensive and continuation phases to determine the relative contributions of iron absorption and iron mobilization from stores during TB treatment and recovery.
Outcome: These studies will provide important new insights into the aetiology of anaemia and iron metabolism in TB patients. The results will provide essential data for evidence-based recommendations on the timing, administration route and efficacy of iron therapy in patients with TB, making possible, a safer and more effective treatment of anaemia in TB while decreasing morbidity and mortality from the disease.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pwani
-
Bagamoyo, Pwani, Tanzania, 0601
- Tb-clinic, Bagamoyo Research and Training Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Females and males 18-45 years of age
- Sputum smear-positive, and confirmed by polymerase chain reaction and culture
- Obtained informed consent
Exclusion Criteria:
- Pregnancy or Lactating (assessed by pregnancy test)
- Body weight <40 kg
- Severe anaemia (Hb <70 g/L)
- HIV positive (assessed by HIV test)
- Positive rapid malaria antigen test
- Intake of mineral/vitamin supplements 2 weeks before and during the study
- Diagnosed metabolic or gastrointestinal disorders, eating disorders or food allergy
- Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 6 months
- Subject who cannot be expected to comply with study protocol (e.g. non-residents to the Bagamoyo Coast region, or subjects who plan to travel or move)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Tuberculosis, no HIV and severe anemia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in iron absorption of stable isotope tracers at week 8
Time Frame: baseline, 8 weeks
|
Stable iron isotopes will be orally administered under standardized conditions and close supervision.
Iron absorption will be calculated from the shift in the normal isotopic abundance in red blood cells; 8 weeks = end of first treatment phase
|
baseline, 8 weeks
|
Change from baseline in iron incorporation of stable isotope tracers at week 8
Time Frame: baseline, 8 weeks
|
Stable iron isotopes will be infused under standardized conditions and close supervision.
Iron incorporation will be calculated from the shift in the normal isotopic abundance in red blood cells; 8 weeks = end of first treatment phase.
|
baseline, 8 weeks
|
Change from baseline in iron absorption of stable isotope tracers at week 24
Time Frame: baseline, 24 weeks
|
Stable iron isotopes will be orally administered under standardized conditions and close supervision.
Iron absorption will be calculated from the shift in the normal isotopic abundance in red blood cells; 24 weeks = end of second treatment phase
|
baseline, 24 weeks
|
Change from baseline in iron incorporation of stable isotope tracers at week 24
Time Frame: baseline, 24 weeks
|
Stable iron isotopes will be infused under standardized conditions and close supervision.
Iron incorporation will be calculated from the shift in the normal isotopic abundance in red blood cells; 24 weeks = end of second treatment phase.
|
baseline, 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in serum hepcidin at week 2
Time Frame: baseline, 2 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 2 weeks
|
Change from baseline in serum hepcidin at week 4
Time Frame: baseline, 4 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 4 weeks
|
Change from baseline in serum hepcidin at week 6
Time Frame: baseline, 6 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 6 weeks
|
Change from baseline in serum hepcidin at week 8
Time Frame: baseline, 8 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 8 weeks
|
Change from baseline in serum hepcidin at week 10
Time Frame: baseline, 10 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 10 weeks
|
Change from baseline in serum hepcidin at week 12
Time Frame: baseline, 12 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 12 weeks
|
Change from baseline in serum hepcidin at week 14
Time Frame: baseline, 14 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 14 weeks
|
Change from baseline in serum hepcidin at week 16
Time Frame: baseline, 16 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 16 weeks
|
Change from baseline in serum hepcidin at week 18
Time Frame: baseline, 18 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 18 weeks
|
Change from baseline in serum hepcidin at week 20
Time Frame: baseline, 20 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 20 weeks
|
Change from baseline in serum hepcidin at week 22
Time Frame: baseline, 22 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 22 weeks
|
Change from baseline in serum hepcidin at week 24
Time Frame: baseline, 24 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 24 weeks
|
Change from baseline in serum hepcidin at week 26
Time Frame: baseline, 26 weeks
|
As a determinant of iron metabolism, serum hepcidin will be measured several times during the study.
|
baseline, 26 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Fe_TB_Study_TZ
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Stable iron isotopes, non-drug intervention
-
Swiss Federal Institute of TechnologyAmerican University of Beirut Medical CenterCompleted
-
Wageningen UniversityInternational Foundation for Science (IFS)Completed
-
Central South UniversityCompleted
-
Institut Claudius RegaudCompletedMetastatic Breast Cancer Starting a Third Line ChemotherapyFrance
-
University Hospital, ToulouseActive, not recruitingMidgut Neuroendocrine TumorsFrance
-
Tianjin Happy Life Technology Co., Ltd.Unknown
-
GlaxoSmithKlineCompletedCancerKorea, Republic of, Hong Kong, Pakistan, Singapore
-
University of MinnesotaPatient-Centered Outcomes Research InstituteCompletedChronic PainUnited States
-
Universidade Estadual Paulista Júlio de Mesquita...Recruiting
-
Purdue Pharma LPCompleted